Table 6 Univariate sensitivity analysis of screening, abnormal findings management and treatment costs (€), Italy 2006.
From: Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy
Screening | Abnormal findings and treatment | Total costs of cervical cancer prevention | |
|---|---|---|---|
Baseline values for all the parameters | 158,288,703 | 22,959,267 | 181,247,970 |
No. of screened women yearly | |||
baseline: extrapolation from ISTAT (N = 6,423,924) | |||
lower case: similar, but excluding overlap between opportunistic and organised screening (N = 6,270,130) | 154,332,393 | 22,825,230 | 177,157,624 |
No. of CIN2/3 found | |||
baseline: estimate from Emilia Romagna cancer registry (N = 6,982) | |||
higher case: extrapolation from GISCi survey (N = 16,571) | 158,288,703 | 34,532,811 | 192,821,515 |
Referral rate | |||
baseline: extrapolation from GISCi survey (2.5%) | |||
lower case: 25th centile of the GISCi survey distribution (1.5%) | 158,288,703 | 20,920,849 | 179,209,552 |
higher case: 75th centile of the GISCi survey distribution (3%) | 158,288,703 | 24,235,135 | 182,523,838 |
ASCUS management | |||
baseline: no triage with HPV test | |||
triage with HPV test (cost 81.60€ according to national tariff) | 158,288,703 | 26,101,216 | 184,389,919 |
triage with HPV test (cost 15.00€) | 158,288,703 | 22,197,251 | 180,485,954 |
Colposcopy setting | |||
baseline: no gynaecological visit | |||
upper case: gynaecological visit for colposcopies performed in opportunistic screening | 158,288,703 | 25,199,706 | 183, 488,409 |
CIN1 treatment | |||
baseline: 37% of CIN1 treated | |||
upper case: 63% of CIN1 treated | 158,288,703 | 26,231,936 | 184,510,639 |
Conisation setting | |||
baseline: inpatient (36% day hospital and 64% full hospitalization) | |||
lower case: outpatient | 158,288,703 | 8,084,711 | 166,373,414 |